FDA panel votes against Aveo's kidney cancer drug

May 2, 2013 5:07 PM

8 0

FDA panel votes against Aveo's kidney cancer drug

(Reuters) - An advisory panel to the Food and Drug Administration recommended that the agency reject a kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc, saying data from the clinical trial were inconsistent.

In a 13-1 vote on Thursday, the panel said Aveo had not shown that the drug's benefits outweighed its risks in a well-controlled study, and said a second trial would be needed before the drug, tivozanib, should be approved.

Read more

To category page

Loading...